Published in Cancer Weekly, March 14th, 2006
According to a recently published article, scientists in England conducted a study "to determine if amino-terminal P1NP is reliable as a predictor of prostate cancer bone metastases and assess its value as a prognostic indicator of disease progression and survival. A cohort of patients with prostate cancer between January 1999 and July 2001 were recruited. Prostate-specific antigen (PSA) and P1NP levels were measured."
"Two years following completion of recruitment, patient notes were reviewed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.